OCGN
Ocugen Inc
-23.15%
$1.24 - $0.95
Feb 7th 2023 - Mar 21st 2023
Mar, 13, 2023
$OCGN Ocugen Inc’s prospects for future market suc... See more
Mar, 13, 2023
And EYPT is best in class in eye therapy in my opinion.
Dec, 15, 2022
Universal flu & cancer vaccine. 💎
Dec, 14, 2022
$NVAX Moderna is curing cancer now.
Dec, 13, 2022
$NVAX Glad to see mRNA technology can Finally be applied in reducing the risk of Cancer relapse with Cell therapy!
Nov, 15, 2022
They have much more valuable cancer drugs in the works, more innovated cutting edge companies where people are going to invest.
Oct, 5, 2022
We were very encouraged to see that the effect was reproducible and was also observed in a second melanoma model with JB/RH cells.
Mar, 13, 2023
$OCGN Ocugen Inc’s prospects for future market success appear strong, given the company’s growing pipeline of gene therapies, strategic partnerships, and innovative technology platforms.
Mar, 13, 2023
And EYPT is best in class in eye therapy in my opinion.
Feb, 7, 2023
They worked with leading experts in the field to develop innovative therapies for a range of ocular diseases, and their products were met with great excitement and anticipation.
Jan, 18, 2023
Since the vaccine is delivered via the nose, right where the virus enters the body, it has the potential to block infection and break the cycle of transmission, as well as prevent lung damage.
Jan, 4, 2023
With that guidance Ocugen has a clear path forward for the first candidate in regenerative cell therapy…future is bright and market potential for that therapy alone is huge 😎